(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots ...

By Michael Erman and Siddhi Mahatole May 6 (Reuters) - Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Why Novavax Stock Is Back on Investor Radars Novavax (NVAX) has been catching investor attention again after recent trading swings, with the stock closing at US$9.06 and showing mixed short term ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

WASHINGTON (AP) — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The news sent ...

Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Novavax was close to going under. In early 2023, it warned investors that it might not have enough funds to finish the year. However, the biotech has made significant changes over the past 18 months.

Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be reporting results this Wednesday before market open. Here’s what you need to know. Novavax beat analysts’ revenue expectations last quarter, ...

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...